Galmed has discovered a proprietary pharmacodynamic blood-based biomarker signature for Aramchol, positioning the company for expansion beyond liver disease. With a new patent, Galmed extended Aramchol's patent protection through September 2039, securing a 15-year exclusivity runway. The company is pursuing oncology partnerships and combination therapy strategies.
Cyborg Score Rationale
Galmed has strong IP protection and a promising lead candidate with biomarker validation, but remains clinical-stage with minimal employee count and negative earnings. The stock has experienced 71.68% decline over the past year, indicating significant execution risk and investor concerns about clinical development success.
Top Insights
Proprietary biomarker signature discovered in Phase 3 ARMOR study reveals multi-system therapeutic potential beyond liver, including cardiometabolic and inflammatory conditions
Aramchol enhances Bayer's regorafenib effect in GI cancer models; Phase 1/2 clinical trial planned for HCC and GI cancers with enrollment starting in 2026
Patent covers combination therapy of Aramchol and Resmetirom (Rezdiffra) for NASH/MASH treatment, opening potential combo-therapy market opportunities
Early-stage pipeline includes Amilo-5MER peptide and MyBiotics microbiome treatment in pre-clinical trials for NASH and fibrosis
Named Competitors
Rezdiffra — NASH/MASH therapy with complementary mechanism to Aramchol
Stivarga — GI cancer standard-of-care drug being combined with Aramchol in planned trials
Recent Developments
(December 2025) Accepted late-breaking abstract for HEP-DART 2025 showing Aramchol enhances regorafenib in GI cancer; Phase 1/2 trial planned for 2026
(May 2025) Identified proprietary biomarker signature for Aramchol from Phase 3 ARMOR study offering expansion potential beyond NASH
(March 2025) Patent granted for Aramchol-Resmetirom combination therapy, extending patent protection to September 2039
Open the full interactive Galmed Pharmaceuticals Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.